SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests — Prolaris® Prostate Cancer Test and MyRisk® Hereditary Cancer Test – into Lumea’s digital pathology platform, BxLink™. This collaboration will streamline the ordering and delivery of molecular tests, enabling heal ...

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company's "Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation" study was awarded SMFM's "Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics." The study found that ...

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company’s “Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation” study was awarded SMFM’s “Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics.” The study found that ...

Myriad Genetics, Inc. (MYGN) recently launched a new educational website, Know More Sooner, which provides comprehensive information about reproductive and prenatal genetic testing. The latest launch should bolster the company’s Prenatal business. MYGN Stock Movement Following the NewsFollowing the news, shares of MYGN rose 3.9% to $12.76 yesterday. According to a survey, the majority of women wanted prenatal screening once they understood how genetic testing can provide insights into their pregnancy’s gene ...

Core Insights - Myriad Genetics has launched a new educational website, "Know More Sooner," aimed at providing comprehensive information about reproductive and prenatal genetic testing [1][2] Group 1: Website Features and Purpose - The "Know More Sooner" website aims to educate users on the benefits of prenatal genetic testing, dispel myths, and provide guidance on screening locations and actions for high-risk results [2] - The site includes real-life patient stories to demonstrate how prenatal screening can assist parents in managing their pregnancies [2] Group 2: Survey Insights - A survey indicated that many women desire prenatal screening once they understand its benefits, yet 40% of respondents reported not being offered noninvasive prenatal testing (NIPT) [3] - The survey was conducted with 1,000 US-based individuals who identified as pregnant or recently pregnant [6] Group 3: Recommendations and Expert Opinions - The American College of Obstetricians and Gynecologists (ACOG) recommends that carrier and cfDNA screening be offered to all pregnant patients, regardless of ancestry, maternal age, or risk of chromosomal abnormalities [4] - Experts from Myriad Genetics emphasize the importance of understanding genetic testing benefits to help women make informed decisions during pregnancy [5] Group 4: Genetic Tests Offered - Myriad Genetics offers three genetic tests for pregnant individuals: - SneakPeek Gender Test, which predicts fetal sex as early as six weeks with over 99% accuracy [8] - Foresight Carrier Screen, identifying risks of passing down serious inherited conditions [8] - Prequel Prenatal Screen, assessing risks for various chromosomal conditions as early as eight weeks [8]

Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online screening tool and received education about genetic testing. The study was published in Obstetrics & Gynecology (also known as The Green Journal) and was highlighted i ...

SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online screening tool and received education about genetic testing. The study was published in Obstetrics & Gynecology (also known as The Green Journal) and was highlighted in the American College of Obstetricians and Gynecologists (ACOG) Daily Bulletin. The study evaluat ...

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2024, and provided full year 2025 financial guidance. Select Preliminary Fourth Quarter and Full Year 2024 Financial ResultsThe company expects the following: Fourth quarter of 2024 total revenues to be between $209 million and $211 million, an increase of approxi ...

Myriad Genetics, Inc. (MYGN) recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who recently revealed her battle with breast cancer. Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program, which features the MyRisk with RiskScore Hereditary Cancer test.The latest collaboration with Storm will bolster the company’s Hereditary Cancer testing business. MYGN Stock’s Likely Trend Following the NewsMyriad Genetic’ ...

Company Announcement - Myriad Genetics announced a partnership with Hannah Storm, a renowned sports broadcaster, to promote the Myriad Genetics Breast Cancer Risk Assessment Program [1] - Hannah Storm will serve as an ambassador for the MyRisk with RiskScore Hereditary Cancer Test, the industry-leading hereditary cancer and polygenic risk prediction test [2] - The partnership aims to raise awareness about the importance of family health history in understanding cancer risks [2] Product Details - MyRisk with RiskScore evaluates 48 genes associated with hereditary cancer risk and provides a five-year and lifetime breast cancer risk assessment [6] - The test identifies genetic changes linked to increased cancer risk for 11 different cancers and combines this with family history and clinical factors like breast density [6] Awareness Campaign - Hannah Storm will share content on her social media platforms about the importance of knowing family health history and having conversations about hereditary cancers [5] - The campaign will encourage women to discuss their family health history with healthcare providers and consider preventive steps [5] Industry Impact - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health and well-being through genetic insights [7] - The company develops genetic tests that assess disease risk, guide treatment decisions, and improve patient care while lowering healthcare costs [7] Personal Story - Hannah Storm was diagnosed with stage zero Ductal Carcinoma in Situ (DCIS) in January 2024, detected through a routine mammogram and subsequent tests [4] - She emphasizes the importance of genetic testing for early detection and understanding potential hereditary risks for her daughters [3]